EFFICACY EVALUATION OF A MONOCLONAL ANTIBODY AGAINST THE EPIDERMAL GROWTH FACTORS RECEPTOR IN THE MODEL OF SUBCUTANEOUS XENOGRAFT IN IMMUNODEFICIENT MICE

EFFICACY EVALUATION OF A MONOCLONAL ANTIBODY AGAINST THE EPIDERMAL GROWTH FACTORS RECEPTOR IN THE MODEL OF SUBCUTANEOUS XENOGRAFT IN IMMUNODEFICIENT MICE

This article presents the results of the comparative antitumor efficacy study of two test articles of therapeutic humanized monoclonal antibodies against epidermal growth factor receptor (EGFR) manufactured by Russian biopharmaceutical company CJSC “Biocad” and the commercial drug “Erbitux®” (Merck,...

Full description

Bibliographic Details
Main Authors: Ya. Yu. Ustyugov, A. A. Aleksandrov, M. V. Artyukova, M. A. Varavko
Format: Article
Language:Russian
Published: Tomsk National Research Medical Center of the Russian Academy of Sciences 2016-02-01
Series:Sibirskij Onkologičeskij Žurnal
Subjects:
a431ns, erbitux®, xenograft, immunodeficient mice, tumor growth inhibition, antitumor efficacy, human epidermoid carcinoma, tumor growth index
Online Access:https://www.siboncoj.ru/jour/article/view/222

Similar Items

Similar Items